Key Points – Fennec Pharmaceuticals reported strong Q1 2026 results, with net product sales rising about 73% year over year to $15.1 million and positive operating cash flow.
Management said it was the sixth straight quarter of sales growth. – The company’s expanded sales force under Project Ignite is starting to pay off, with the target prescriber base growing from roughly 1,300 to more than 5,000
Executives said the broader reach is driving demand from both new and existing prescribers, while the Fennec HEARS support program boosted completed infusions and hit an 80% conversion benchmark for the first time. – Management also highlighted growing clinical interest in PEDMARK beyond pediatrics, including investigator-initiated studies in AYA and adult cancer patients and multiple ASCO abstracts. Fennec said its cash position remains strong enough, alongside projected revenue, to support the current operating plan through 2026. Adherex Technologies (NASDAQ:FENC) executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow and early signs that recent sales force investments are increasing demand.
On the company’s first-quarter 2026 earnings call, Chief Executive Officer Jeffrey S. Hackman called 2026 “a defining period” for Fennec, citing progress in commercial execution, clinical interest in PEDMARK and the company’s financial position. PEDMARK is approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors to reduce the risk of cisplatin-induced ototoxicity, or permanent hearing loss.